Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results - ANI Pharmaceuticals (NASDA